These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38259071)

  • 1. A genetic variant of
    Luo M; Dong C; Liang X; Na R; Zhou B; Hou J; Jiang D-K
    J Clin Microbiol; 2024 Feb; 62(2):e0139623. PubMed ID: 38259071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL13 variant predicts pegylated-interferon α treatment response in HBeAg-positive chronic hepatitis B patients.
    Luo M; Zhang L; Yang C; Zhou B; Hou J; Jiang DK
    J Med Virol; 2023 Jul; 95(7):e28963. PubMed ID: 37470204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients.
    Chen J; Hou J; Na R; Zhou B; Hou J; Jiang DK
    Clin Pharmacol Ther; 2024 Feb; 115(2):361-370. PubMed ID: 38018367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients.
    Chen H; Sun J; Zhou B; Peng J; Xie Q; Liang X; Fan R; Conran C; Xu J; Ji Y; Zhang X; Sun L; Jia J; Wang G; Hou J; Jiang DK
    Aliment Pharmacol Ther; 2020 Feb; 51(4):469-478. PubMed ID: 31943297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
    Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
    World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.
    Huang J; Zhang K; Chen W; Liao J; Luo X; Chen R
    Sci Rep; 2017 Oct; 7(1):13383. PubMed ID: 29042662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.
    Zhang M; Li G; Shang J; Pan C; Zhang M; Yin Z; Xie Q; Peng Y; Mao Q; Xiao X; Jiang Y; Luo K; Xu Y; Ding H; Fan W; Diego V; Pourkarim MR; De Clercq E; Wang G; Gong G
    Hepatol Int; 2020 Mar; 14(2):212-224. PubMed ID: 32100261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy.
    Lou S; Wang J; Chen J; Xie H; Chen H; Zhou B; Zhang B; Hou J; Jiang DK
    J Infect Dis; 2023 Sep; 228(6):694-703. PubMed ID: 36932045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure.
    Weng M; Zeng WZ; Wu XL; Zhang Y; Jiang MD; Wang Z; Zhou DJ; He X
    Virol J; 2013 Sep; 10():277. PubMed ID: 24010768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-α therapy: A prospective cohort study in China.
    Qi X; Li F; Zhang Y; Zhu H; Yang F; Li X; Jiang X; Chen L; Huang Y; Zhang J
    J Med Virol; 2022 Sep; 94(9):4449-4458. PubMed ID: 35610746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
    Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
    Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
    Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
    Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.